MediciNova announces update of Phase 2/3 MN-166 trial at NEALS meeting

MediciNova (MNOV) announced the lead Principal Investigator of this clinical trial, Bjorn Oskarsson, MD, FAAN presented the update of an ongoing Phase 2/3 clinical trial of MN-166 in Amyotrophic Lateral Sclerosis patients at the 2024 Annual NEALS Meeting being held virtually on Oct 21-24, 2024. The presentation entitled “COMBAT-ALS Phase 2b/3 Trial of MN-166 (Ibudilast) in ALS: Study Design and Trial Update” was given by Dr. Oskarsson during the poster session. Dr. Oskarsson discussed the background of MN-166 (ibudilast), scientific rationale, study objectives, study design, major inclusion criteria and enrollment update as of October 18, 2024. Additionally, he discussed the new NIH funding Expand Access Protocol clinical trial in ALS patients.